Roche Just Crashed the Obesity Party. Lilly and Novo Should Be Nervous.

Breaking that down further: nearly 96% of patients lost at least 5% of their body weight. About 48% lost at least 20%. And more than a quarter of patients, 26.1%, lost 30% or more of their body weight. For a Phase II trial, those are the kind of results that make competitors squirm.

Perhaps the most commercially important detail? Only about 2% of patients in the type 2 diabetes trial discontinued due to side effects, with most adverse events being the mild-to-moderate GI issues (nausea, mostly) that are basically table stakes for this drug class. That's a low dropout rate, and tolerability could end up being a real differentiator.

Wall Street Shrugged. That Might Be the Opportunity.

You'd think data like this would send Roche's stock soaring. It didn't. Shares actually rose about 2.2% in early Zurich trading after the readout. Vontobel's Stefan Schneider was bullish, calling the profile competitive with sustained weight loss and meaningful glucose improvements.

The muted reaction tells you something important about where the obesity market stands right now. Investors aren't paying for Phase II promise anymore; they want Phase III proof and a clear commercial story. Roche still needs to demonstrate it can take this drug across the finish line and carve out real market share against entrenched competitors.

The Obesity Duopoly Is Cracking

For the past few years, Lilly and Novo have essentially owned the GLP-1 obesity market. Lilly has tirzepatide (Zepbound), its newly approved oral option orforglipron (Foundayo), and the triple agonist retatrutide in Phase III. Novo has semaglutide (Wegovy), CagriSema, and oral semaglutide in late-stage development.

But the cozy two-player game is ending. Roche is pushing enicepatide into Phase III while also developing an oral GLP-1 (CT-996) and an amylin analog called petrelintide through a partnership with Zealand Pharma. Amgen has MariTide, a once-monthly injectable that could win on convenience alone. Viking Therapeutics is advancing VK-2735 in both injectable and oral forms, with no fasting requirement for the pill version.

Then there's Boehringer Ingelheim with survodutide, AstraZeneca with elecoglipron, and a handful of others nipping at the edges. The obesity market is starting to look less like a tennis match and more like a royal rumble.

The Repricing Is Already Happening

This fragmentation is putting real pressure on the incumbents, especially Novo Nordisk. Novo's stock has been selling off more sharply than Lilly's in recent months, as investors worry about pricing pressure, competitive threats, and whether the company can rebuild its obesity growth narrative. Lilly, meanwhile, has been comparatively insulated, partly because it captured more than 30% of new U.S. oral obesity patients and has the deeper pipeline.

But both giants face the same structural headwind: the long-term assumption of a $150 billion obesity market is getting stress-tested. Lower U.S. GLP-1 prices, cash-pay competition, and the eventual arrival of off-patent semaglutide are all compressing future revenue projections.

What Comes Next

Roche's enicepatide isn't going to dethrone Zepbound or Wegovy tomorrow. Phase III trials take years, and moving from promising mid-stage data to commercial blockbuster is one of the hardest things to do in pharma. Just ask the graveyard of drugs that looked great in Phase II and flopped later.

But the trajectory matters. With competitive weight loss, strong diabetes data, a low discontinuation rate, and no weight-loss plateau in sight, Roche has a legitimate shot at becoming the third major player in obesity. If Phase III confirms what Phase II is showing, Roche's Carmot acquisition could end up looking like one of the smartest deals of the decade.

For Lilly and Novo, the message is clear: the moat around the obesity kingdom just got a little shallower. And there are a lot more invaders on the way.

Sarepta's Worst Week Just Rewrote the Gene Therapy Playbook

Sarepta slapped a black box warning on its Duchenne gene therapy Elevidys and cut 36% of its workforce in one brutal announcement. The fallout raises hard questions about the commercial future of accelerated-approval gene therapies in rare disease.